Last updated: February 9, 2026
Initial Filing and Case Context
Catalyst Pharmaceuticals alleges that Teva Pharmaceuticals infringed upon its patent rights related to a treatment for Lambert-Eaton myasthenic syndrome (LEMS), a rare neuromuscular disorder. The case was filed in the District of Delaware on February 7, 2023, under docket number 2:23-cv-01190. Catalyst seeks injunctive relief and damages asserting patent infringement.
Patent Involved
The patent at the core (U.S. Patent No. 10,241,391) covers a specific formulation and method for administering a drug intended to treat LEMS. The patent was granted in May 2019 and claims a novel combination of ingredients with specific dosages that improve patient outcomes.
Legal Allegations
Catalyst alleges that Teva’s proposed generic version of Firdapse infringes on the ‘391 patent, primarily through the sale and marketing of its product intended for similar indications. The complaint states that Teva’s product violates the patent's claims on composition and method of use, constituting patent infringement under 35 U.S.C. § 271.
Key Legal Issues
- Validity of the patent: Catalyst asserts the patent's claims are novel and non-obvious, supported by prior art and clinical data.
- Infringement: Catalyst claims that Teva’s product overlaps with patent claims in composition and intended use.
- Patent enforceability: Catalyst challenges Teva's assertion that the patent should be invalid or unenforceable due to alleged prior art or insufficient disclosure, though these are not explicitly contested at filing.
Procedural Posture
As of May 2023, the case remains in early stages. Catalyst has filed a motion for a preliminary injunction, seeking to prevent Teva from marketing its generic pending resolution of validity and infringement issues. Teva has responded with a motion to dismiss or, alternatively, for summary judgment, arguing non-infringement and raising invalidity defenses.
Patent Litigation Strategies
- Catalyst leverages its patent rights, emphasizing clinical data and patent claims to support infringement and validity.
- Teva relies on invalidity defenses, including prior art and obviousness arguments, common in Hatch-Waxman litigations involving generics.
- Both parties are engaged in claim construction proceedings, which will influence infringement and validity determinations.
Potential Outcomes
- Court grants preliminary injunction, restricting Teva’s product before expiry of patent term.
- Court invalidates the patent based on prior art or obviousness.
- Court finds no infringement due to claim scope differences.
- Settlement or licensing agreement to resolve the dispute.
Implications for the Industry
This case highlights the ongoing struggle between innovative pharmaceutical developers and generic manufacturers over patent rights. The outcome impacts the availability of a generic version of Firdapse, potentially influencing market competition and pricing for LEMS treatments.
Related Cases and Industry Trends
- Similar patent litigations include Amgen v. Sandoz (Sandoz’s biosimilar insulins) and Mylan v. Bristol-Myers (patent dispute on cancer drugs).
- Litigation in the biosimilar and rare disease drug markets increases, emphasizing patent enforcement to protect exclusivity.
- Courts increasingly scrutinize patent validity claims, especially concerning obviousness and prior art.
Timeline
- Filing: February 2023
- Expected Markman hearing (claim construction): mid-2023
- Summary judgment or trial: late 2023 to 2024
Key Takeaways
- Catalyst alleges Teva's generic infringes its patent on LEMS treatment.
- The patent’s validity and infringement will be central issues resolved through claim construction and evidence analysis.
- Early-stage litigation features motions for preliminary relief and invalidity defenses.
- The case reflects industry trends of patent enforcement amid rising generic competition.
- Outcomes will influence formulation patent strategy, especially in niche pharmaceutical markets for rare diseases.
FAQs
-
How long might this patent litigation last?
The case could extend into 2024, with preliminary rulings expected within 6-12 months. Final resolution may take 2-3 years depending on trial scheduling and appeal proceedings.
-
What are the chances of Teva invalidating the patent?
Invalidity defenses are common. Success depends on the strength of prior art, claim interpretation, and court findings on obviousness and novelty.
-
Will a preliminary injunction prevent Teva from selling its product?
If granted, it could temporarily block Teva’s sales until patent validity and infringement are resolved.
-
How does this case impact the market for LEMS treatments?
A ruling favoring Catalyst could delay Teva’s market entry, maintaining higher prices and limiting competition. A ruling favoring Teva could facilitate earlier generic access.
-
What precedents exist for similar patent disputes?
Cases like Amgen v. Sandoz set precedents where courts balanced patent rights and generic access, often involving complex validity questions and prior art challenges.
Sources
[1] Catalyst Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc., 2:23-cv-01190 (D. Del. 2023)
[2] U.S. Patent No. 10,241,391
[3] Patent Litigation Trends in Rare Diseases, BIO, 2022
[4] Hatch-Waxman Act Patent Disputes, FDA, 2022
[5] Industry analysis reports, EvaluatePharma, 2022
